Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

ERR2278849

—

99f5cc54-0e00-5bca-a428-4e37cc9c2ff1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.540
  • INTERFERON_GAMMA_RESPONSE+0.460
  • TNFA_SIGNALING_VIA_NFKB+0.400
  • IL6_JAK_STAT3_SIGNALING+0.390
  • ALLOGRAFT_REJECTION+0.380
  • INFLAMMATORY_RESPONSE+0.370
  • NOTCH_SIGNALING+0.370
  • P53_PATHWAY+0.360
  • CHOLESTEROL_HOMEOSTASIS+0.340
  • IL2_STAT5_SIGNALING+0.300

Top 10 suppressed

  • E2F_TARGETS-0.640
  • G2M_CHECKPOINT-0.570
  • MYC_TARGETS_V2-0.560
  • MYC_TARGETS_V1-0.510
  • MITOTIC_SPINDLE-0.290
  • OXIDATIVE_PHOSPHORYLATION-0.290
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.250
  • DNA_REPAIR-0.240
  • UV_RESPONSE_DN-0.190
  • PANCREAS_BETA_CELLS-0.180

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

7 twins match this tumor's tissue · 3 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CV-A45O-01A-21R-A24H-07
head-neck@1
——0.891
2SJBT031351_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.873
3TCGA-CN-6013-01A-11R-1686-07
head-neck@1
——0.866
4ERR2208944
melanoma-umap@29
——0.854
5SRR8613709
breast-umap@18
—A0.850
6TCGA-EW-A1PE-01A-11R-A144-07
breast-umap@18
—B0.850
7b1dde645-b48d-44e0-9fe0-2af02470ffb5
colon-landscapes@1
——0.848
8SRR6013477
lung-landscapes@6
—cohortMD20.843
9BS_D3YBV7KB
brain-umap@2
low-grade glioma—0.843
10BS_ZV9Z3SY6
brain-umap@2
pilocytic astrocytoma—0.840

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.540Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.460Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.400Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.390Inavolisib— uncovered
ALLOGRAFT_REJECTION0.380Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.370Idelalisib— uncovered
NOTCH_SIGNALING0.370Inavolisib— uncovered
P53_PATHWAY0.360Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.340Remibrutinib— uncovered
IL2_STAT5_SIGNALING0.300Idelalisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
COMPLEMENT0.280Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.280Inavolisib— uncovered
KRAS_SIGNALING_UP0.260Inavolisib— uncovered
APOPTOSIS0.240Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.220Idelalisib— uncovered
APICAL_SURFACE0.210Temsirolimus— uncovered
HYPOXIA0.200Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.200Inavolisib— uncovered
COAGULATION0.170Binimetinib— uncovered